Halozyme to Present at the Jefferies 3rd Annual Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Jun. 10, 2009-- Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced that management will present at the Jefferies 3^rd Annual Healthcare Conference on Wednesday, June 17, 2009 at 9:00 a.m. ET (6:00 a.m. PT) in New York City.

To listen to the audio webcast of the presentation live or after the event, please visit the company's Web site at https://www.halozyme.com. The replay will be available for 90 days after the presentation.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID™. The product candidates in Halozyme's research pipeline target multiple areas of significant unmet medical need. For more information visit https://www.halozyme.com.

Source: Halozyme Therapeutics, Inc.

HalozymeRobert H. UhlSenior Director, Investor [email protected]